Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cesare Gridelli

Showing results (141-150 of 357) with videos related to

Pageof 36
Sort By:
Clinical Lung Cancer|July 25, 2008
An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trialCesare Gridelli, Charles Butts, Fortunato Ciardiello, et al.
Journal of Thoracic Disease|July 1, 2014
Cetuximab in advanced non-small cell lung cancer (NSCLC): the showdown?Assunta Sgambato, Francesca Casaluce, Paolo Maione, et al.
Expert Opinion on Investigational Drugs|July 5, 2017
Selumetinib for the treatment of non-small cell lung cancerFrancesca Casaluce, Assunta Sgambato, Paolo Maione, et al.
Cancer Treatment Reviews|August 13, 2013
ALK inhibitors in the treatment of advanced NSCLCCesare Gridelli, Solange Peters, Assunta Sgambato, et al.
Current Genomics|May 20, 2009
The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancerClorinda Schettino, Maria A Bareschino, Paolo Maione, et al.
Current Drug Targets|April 24, 2010
Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapyAntonio Rossi, Paolo Maione, Paola Claudia Sacco, et al.
Lung Cancer (Amsterdam, Netherlands)|February 17, 2005
Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical casesAntonio Rossi, Paolo Maione, Filomena Del Gaizo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2013
Reply to V. Lorusso et alCesare Gridelli, Ciro Gallo, Charles A Butts, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 3, 2009
Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapyCesare Gridelli, Amin M Haiderali, Mark W Russo, et al.
Therapeutic Advances in Medical Oncology|September 2, 2015
Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical applicationPaolo Maione, Paola Claudia Sacco, Assunta Sgambato, et al.
Pageof 36

Showing results (141-150 of 357) with videos related to

Sort By:
Pageof 36
Clinical Lung Cancer|July 25, 2008
An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trialCesare Gridelli, Charles Butts, Fortunato Ciardiello, et al.
Journal of Thoracic Disease|July 1, 2014
Cetuximab in advanced non-small cell lung cancer (NSCLC): the showdown?Assunta Sgambato, Francesca Casaluce, Paolo Maione, et al.
Expert Opinion on Investigational Drugs|July 5, 2017
Selumetinib for the treatment of non-small cell lung cancerFrancesca Casaluce, Assunta Sgambato, Paolo Maione, et al.
Cancer Treatment Reviews|August 13, 2013
ALK inhibitors in the treatment of advanced NSCLCCesare Gridelli, Solange Peters, Assunta Sgambato, et al.
Current Genomics|May 20, 2009
The potential role of pharmacogenomic and genomic in the adjuvant treatment of early stage non small cell lung cancerClorinda Schettino, Maria A Bareschino, Paolo Maione, et al.
Current Drug Targets|April 24, 2010
Vascular endothelial growth factor receptor as target for advanced non-small cell lung cancer therapyAntonio Rossi, Paolo Maione, Paola Claudia Sacco, et al.
Lung Cancer (Amsterdam, Netherlands)|February 17, 2005
Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical casesAntonio Rossi, Paolo Maione, Filomena Del Gaizo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2013
Reply to V. Lorusso et alCesare Gridelli, Ciro Gallo, Charles A Butts, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 3, 2009
Casopitant improves the quality of life in patients receiving highly emetogenic chemotherapyCesare Gridelli, Amin M Haiderali, Mark W Russo, et al.
Therapeutic Advances in Medical Oncology|September 2, 2015
Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical applicationPaolo Maione, Paola Claudia Sacco, Assunta Sgambato, et al.
Pageof 36